Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Epidermal growth factor vs best supportive care Survival rates at 3 years · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | RR 1.45 [0.82, 2.54] | 2 studies · 458 participants | Low |
Epidermal growth factor vs best supportive care Survival rates at 5 years · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | RR 3.4 [1.02, 11.27] | 1 study · 378 participants | Low |
Epidermal growth factor vs best supportive care Health‐related quality of life · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | MD 7.9 | 1 study · 86 participants | Very low |
TG4010 added to chemotherapy vs chemotherapy alone Progression‐free survival · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | HR 0.74 [0.55, 0.99] | 1 study · 222 participants | Low |
TG4010 added to chemotherapy vs chemotherapy alone Participants with at least one serious adverse event · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | RR 0.7 [0.23, 2.19] | 2 studies · 362 participants | Very low |
TG4010 added to chemotherapy vs chemotherapy alone Survival rates at 3 years · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | RR 1 [0.3, 3.31] | 1 study · 148 participants | Low |
TG4010 added to chemotherapy vs chemotherapy alone Survival rates at 5 years · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | no estimate extracted | NR | No studies |
TG4010 added to chemotherapy vs chemotherapy alone Health‐related quality of life · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | no estimate extracted | NR | No studies |
Epidermal growth factor vs best supportive care Overall survival · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | HR 0.82 [0.66, 1.02] | 1 study · 378 participants | Low |
Epidermal growth factor vs best supportive care Progression‐free survival · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | no estimate extracted | NR | No studies |
Epidermal growth factor vs best supportive care Participants with at least one serious adverse event · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | RR 1.32 [0.88, 1.98] | 2 studies · 458 participants | Low |
Metformin vs placebo eGFR: change ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | 3 studies · 505 participants | Low |
Metformin vs active control Serious adverse events ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 1.16 [0.79, 1.71] | 2 studies · 5545 participants | Moderate |
Metformin vs active control Withdrew due to intolerance ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 0.92 [0.79, 1.08] | 3 studies · 5593 participants | Moderate |
Metformin vs active control Dosing and tolerance ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | 3 studies · 3 participants | Moderate |
Metformin vs active control Kidney failure · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | NR | No studies |
Metformin vs active control UACR (% change) ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | 2 studies · 3836 participants | Low |
Metformin vs placebo All‐cause death ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 1 [0.76, 1.32] | 3 studies · 865 participants | Very low |
Metformin vs placebo Serious adverse events ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 1.15 [0.76, 1.72] | 3 studies · 576 participants | Moderate |
Metformin vs placebo Withdrew due to intolerance ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 2.19 [1.46, 3.27] | 4 studies · 646 participants | Moderate |
Metformin vs placebo Dose tolerability ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | 3 studies · 576 participants | Moderate |
Metformin vs placebo Kidney failure (median · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 1.2 [0.17, 8.49] | 1 study · 753 participants | Very low |
Metformin vs placebo Change in proteinuria (1 year) · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | 2 studies · 100 participants | Very low |
Metformin vs active control eGFR: change (4 years) · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | no estimate extracted | 1 study · 3914 participants | Very low |
Metformin vs active control All‐cause death ( · preventing the progression of CKD Metformin for preventing the progression of chronic kidney disease (2024) · Cochrane | RR 0.95 [0.63, 1.43] | 3 studies · 5608 participants | Low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Symptoms of anxiety · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 5 studies · 431 participants | Very low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Symptoms of depression · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 2 studies · 166 participants | Very low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Medical contacts Assessed as hospital admissions, ED presentations or asthma‐related urgent care visits. · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 5 studies · 636 participants | Very low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Asthma attacks · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 3 studies · 129 participants | Very low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Asthma symptoms · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 11 studies · 720 participants | Very low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Medication use · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 8 studies · 822 participants | Very low |
Psychological interventions vs usual care, no intervention, or treatment with no psychological component Quality of life · adolescents with asthma Psychological interventions for asthma in children and adolescents (2024) · Cochrane | no estimate extracted | 6 studies · 653 participants | Very low |
Intervention NR Time to hemostasis (seconds) · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | 7 studies · 498 participants | Low |
Intervention NR Failure of hemostatic intervention ( · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | RR 0.46 [0.35, 0.61] | 17 studies · 2120 participants | Very low |
Intervention NR Intraoperative blood loss (mL) · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | 3 studies · 266 participants | Low |
Intervention NR Operating time (minutes) · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | 4 studies · 436 participants | Low |
Intervention NR Death from bleeding complications (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Postoperative bleeding (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | RR 0.78 [0.59, 1.04] | 9 studies · 1216 participants | Low |
Intervention NR Unplanned return to the operating room (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane | RR 0.27 [0.04, 1.69] | 8 studies · 721 participants | Low |
Doxepin cream vs oral antihistamine Change in burn‐related pruritus (VAS) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 2 studies · 49 participants | Low |
Ondansetron vs diphenhydramine (antihistamine) Change in burn‐related pruritus (NAS) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 1 study · 38 participants | Moderate |
Ondansetron vs diphenhydramine (antihistamine) Adverse events · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Ondansetron vs diphenhydramine (antihistamine) Pain · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Enalapril ointment vs placebo Change in burn‐related pruritus (Scoring table for itching) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 1 study · 60 participants | Moderate |
Enalapril ointment vs placebo Adverse events · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Enalapril ointment vs placebo Pain · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Massage therapy vs standard care Change in burn‐related pruritus Itching scale ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 2 studies · 166 participants | Low |
Massage therapy vs standard care Adverse events · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Massage therapy vs standard care Pain VAS for pain ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 2 studies · 166 participants | Low |
Extracorporeal shock wave therapy vs sham Change in burn‐related pruritus NRS ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 2 studies · 91 participants | Low |